At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AMGN Amgen
Trading 06-05 11:53:09 EDT
354.03
+8.43
+2.44%
High355.19Low347.66Vol952.50K
Open348.68D1 Closing345.60Amplitude2.18%
Mkt Cap190.64BTradable Cap190.11BTotal Shares538.48M
T/O335.95MT/O Rate0.18%Tradable Shares536.99M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Amgen price target lowered to $389 from $425 at Goldman Sachs
TIPRANKS  ·  20:55
Amgen price target lowered to $389 from $425 at Goldman Sachs
Amgen to present at Goldman Sachs Global Healthcare Conference webcast
Reuters  ·  04:01
Amgen to present at Goldman Sachs Global Healthcare Conference webcast
Movement Alert｜Amgen Rises 3.01% in Regular Trading, EU Approves Its Small Cell Lung Cancer Drug Imdylltra
Market Focus  ·  06-04 22:07
Movement Alert｜Amgen Rises 3.01% in Regular Trading, EU Approves Its Small Cell Lung Cancer Drug Imdylltra
Sino Biopharmaceutical Stock Sheds 1.5% in Hong Kong, Underperforms Competitors
Dow Jones  ·  06-04 16:33
Sino Biopharmaceutical Stock Sheds 1.5% in Hong Kong, Underperforms Competitors
Assessing Amgen (AMGN) Valuation After Imdelltra Approval And Concerns Over Tavneos And Prolia
Simply Wall St.  ·  06-04 13:29
Assessing Amgen (AMGN) Valuation After Imdelltra Approval And Concerns Over Tavneos And Prolia
Amgen CEO Bradway says AI reshapes drug discovery and development
Reuters  ·  06-04 06:11
Amgen CEO Bradway says AI reshapes drug discovery and development
Amgen Inc. Stock Outperforms Competitors On Strong Trading Day
Dow Jones  ·  06-04 04:35
Amgen Inc. Stock Outperforms Competitors On Strong Trading Day
Movement Alert｜Amgen Rises 3.06% in Regular Trading, EU Approves Its Small Cell Lung Cancer Drug Imdylltra
Market Focus  ·  06-04 03:57
Movement Alert｜Amgen Rises 3.06% in Regular Trading, EU Approves Its Small Cell Lung Cancer Drug Imdylltra
EU approves Amgen’s Imdylltra for advanced small-cell lung cancer
Reuters  ·  06-03 21:29
EU approves Amgen’s Imdylltra for advanced small-cell lung cancer
EU Approval Of IMDYLLTRA Puts Amgen’s Lung Cancer Ambitions In Focus
Simply Wall St.  ·  06-03 12:52
EU Approval Of IMDYLLTRA Puts Amgen’s Lung Cancer Ambitions In Focus
Health Rounds: Radiation-emitting implant improves outcomes after brain cancer surgery
Reuters  ·  06-03 00:55
Health Rounds: Radiation-emitting implant improves outcomes after brain cancer surgery
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Thermo Fisher (TMO)
TIPRANKS  ·  06-02
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Thermo Fisher (TMO)
Sino Biopharmaceutical Stock Slides 1.4% in Hong Kong, Underperforms Competitors
Dow Jones  ·  06-02
Sino Biopharmaceutical Stock Slides 1.4% in Hong Kong, Underperforms Competitors
Healthcare and 2 Other Lagging Sectors to Buy -- Barrons.com
Dow Jones  ·  06-02
Healthcare and 2 Other Lagging Sectors to Buy -- Barrons.com
European Commission approves Amgen’s Imdylltra for ES-SCLC
TIPRANKS  ·  06-02
European Commission approves Amgen’s Imdylltra for ES-SCLC
Amgen Inc. Stock Underperforms Monday When Compared To Competitors
Dow Jones  ·  06-02
Amgen Inc. Stock Underperforms Monday When Compared To Competitors
EU grants Amgen approval for Imdylltra in extensive-stage small cell lung cancer
Reuters  ·  06-02
EU grants Amgen approval for Imdylltra in extensive-stage small cell lung cancer
European Commission Approves Amgen's Imdylltra® for the Treatment of Extensive-Stage Small Cell Lung Cancer
THOMSON REUTERS  ·  06-02
European Commission Approves Amgen's Imdylltra® for the Treatment of Extensive-Stage Small Cell Lung Cancer
Movement Alert｜Amgen Falls 3.02% in Regular Trading, FDA Proposes Withdrawal of Rare Disease Drug Over Fatal Liver Injury Cases
Market Focus  ·  06-01
Movement Alert｜Amgen Falls 3.02% in Regular Trading, FDA Proposes Withdrawal of Rare Disease Drug Over Fatal Liver Injury Cases
Mabwell Bioscience proposes new board slate as four directors retire
Reuters  ·  05-31
Mabwell Bioscience proposes new board slate as four directors retire

Introduction

Company Name.
Amgen
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Issue price:
--